216 related articles for article (PubMed ID: 28389356)
1. Compatibility of Tanshinone IIA and Astragaloside IV in attenuating hypoxia-induced cardiomyocytes injury.
Wang D; Liu Y; Zhong G; Wang Y; Zhang T; Zhao Z; Yan X; Liu Q
J Ethnopharmacol; 2017 May; 204():67-76. PubMed ID: 28389356
[TBL] [Abstract][Full Text] [Related]
2. Effect of astragaloside IV against rat myocardial cell apoptosis induced by oxidative stress via mitochondrial ATP-sensitive potassium channels.
Guan FY; Yang SJ; Liu J; Yang SR
Mol Med Rep; 2015 Jul; 12(1):371-6. PubMed ID: 25739067
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway.
Jia Y; Zuo D; Li Z; Liu H; Dai Z; Cai J; Pang L; Wu Y
Chem Pharm Bull (Tokyo); 2014; 62(1):45-53. PubMed ID: 24390491
[TBL] [Abstract][Full Text] [Related]
4. Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes.
Zhang L; Wu Y; Li Y; Xu C; Li X; Zhu D; Zhang Y; Xing S; Wang H; Zhang Z; Shan H
Cell Physiol Biochem; 2012; 30(4):843-52. PubMed ID: 22890296
[TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways.
Yin B; Hou XW; Lu ML
Acta Pharmacol Sin; 2019 May; 40(5):599-607. PubMed ID: 30030530
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a.
Gong L; Chang H; Zhang J; Guo G; Shi J; Xu H
Cell Physiol Biochem; 2018; 49(6):2240-2253. PubMed ID: 30257251
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV attenuates apoptosis of hypertrophic cardiomyocyte through inhibiting oxidative stress and calpain-1 activation.
Mei M; Tang F; Lu M; He X; Wang H; Hou X; Hu J; Xu C; Han R
Environ Toxicol Pharmacol; 2015 Nov; 40(3):764-73. PubMed ID: 26433482
[TBL] [Abstract][Full Text] [Related]
8. Asperosaponin VI protects cardiac myocytes from hypoxia-induced apoptosis via activation of the PI3K/Akt and CREB pathways.
Li C; Tian J; Li G; Jiang W; Xing Y; Hou J; Zhu H; Xu H; Zhang G; Liu Z; Ye Z
Eur J Pharmacol; 2010 Dec; 649(1-3):100-7. PubMed ID: 20863824
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.
Xie J; Liu JH; Liu H; Liao XZ; Chen Y; Lin MG; Gu YY; Liu TL; Wang DM; Ge H; Mo SL
BMC Cancer; 2016 Nov; 16(1):899. PubMed ID: 27863471
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV attenuates injury caused by myocardial ischemia/reperfusion in rats via regulation of toll-like receptor 4/nuclear factor-κB signaling pathway.
Lu M; Tang F; Zhang J; Luan A; Mei M; Xu C; Zhang S; Wang H; Maslov LN
Phytother Res; 2015 Apr; 29(4):599-606. PubMed ID: 25604645
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.
Zhang S; Tang F; Yang Y; Lu M; Luan A; Zhang J; Yang J; Wang H
PLoS One; 2015; 10(3):e0118759. PubMed ID: 25738576
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway.
Hong HJ; Liu JC; Chen PY; Chen JJ; Chan P; Cheng TH
Int J Cardiol; 2012 May; 157(2):174-9. PubMed ID: 21190747
[TBL] [Abstract][Full Text] [Related]
13. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
[TBL] [Abstract][Full Text] [Related]
14. Astragaloside IV prevents lipopolysaccharide-induced injury in H9C2 cardiomyocytes.
Wang SG; Xu Y; Xie H; Wang W; Chen XH
Chin J Nat Med; 2015 Feb; 13(2):127-32. PubMed ID: 25769895
[TBL] [Abstract][Full Text] [Related]
15. Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a.
Wu Y; Fan Z; Chen Z; Hu J; Cui J; Liu Y; Wang Y; Guo B; Shen J; Xie L
Mol Cell Biochem; 2020 Jul; 470(1-2):41-51. PubMed ID: 32394311
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes.
Zhang Y; Zhang L; Chu W; Wang B; Zhang J; Zhao M; Li X; Li B; Lu Y; Yang B; Shan H
Cell Physiol Biochem; 2010; 26(6):991-8. PubMed ID: 21220930
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between Beclin-1-dependent autophagy and caspase‑dependent apoptosis induced by tanshinone IIA in human osteosarcoma MG-63 cells.
Ma K; Zhang C; Huang MY; Guo YX; Hu GQ
Oncol Rep; 2016 Oct; 36(4):1807-18. PubMed ID: 27499329
[TBL] [Abstract][Full Text] [Related]
18. Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation.
Yang R; Liu A; Ma X; Li L; Su D; Liu J
J Cardiovasc Pharmacol; 2008 Apr; 51(4):396-401. PubMed ID: 18427283
[TBL] [Abstract][Full Text] [Related]
19. Synergism and mechanism of Astragaloside IV combined with Ginsenoside Rg1 against autophagic injury of PC12 cells induced by oxygen glucose deprivation/reoxygenation.
Huang XP; Ding H; Yang XQ; Li JX; Tang B; Liu XD; Tang YH; Deng CQ
Biomed Pharmacother; 2017 May; 89():124-134. PubMed ID: 28219050
[TBL] [Abstract][Full Text] [Related]
20. Immune regulation mechanism of Astragaloside IV on RAW264.7 cells through activating the NF-κB/MAPK signaling pathway.
Li Y; Meng T; Hao N; Tao H; Zou S; Li M; Ming P; Ding H; Dong J; Feng S; Li J; Wang X; Wu J
Int Immunopharmacol; 2017 Aug; 49():38-49. PubMed ID: 28550733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
